Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on CHRS.
Posts Tagged ‘NASDAQ:CHRS’
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript November 6, 2024Coherus BioSciences, Inc. beats earnings expectations.
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript May 10, 2024.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21.
Here’s Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS)
Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Strategy” fourth quarter 2023 investor letter.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.
Should You Invest in Coherus BioSciences (CHRS)?
Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter...
Will Coherus BioSciences (CHRS) Stock Bounce Back?
Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” second quarter 2022 investor letter.
10 Biotech Stocks to Buy Today According to Kerr Neilson’s Platinum Asset Management
In this piece, we will take a look at the ten biotechnology stocks to buy today according to Kerr Neilson's Platinum Asset Management.
10 Best Healthcare Stocks Under $20 According to Michael Castor’s Sio Capital
In this article, we discuss the 10 best healthcare stocks under $20 according to Michael Castor's Sio Capital.
Hedge Funds Are Warming Up To Coherus Biosciences Inc (CHRS)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change...
Hedge Funds Are Selling Coherus Biosciences Inc (CHRS)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file ...
Did Hedge Funds Make The Right Call On Coherus Biosciences Inc (CHRS) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Aren’t Done Buying Coherus Biosciences Inc (CHRS)
In this article we will check out the progression of hedge fund sentiment towards Coherus Biosciences Inc (NASDAQ:CHRS) and determine whether it is a good investment right now...
Were Hedge Funds Right About Coherus Biosciences Inc (CHRS)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds.
Is Coherus Biosciences Inc (CHRS) A Good Stock To Buy ?
Is Coherus Biosciences Inc (NASDAQ:CHRS) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending...
Hedge Funds Have Never Been More Bullish On Coherus Biosciences Inc (CHRS)
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment...
Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc (CHRS)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited...
Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Should You Buy Coherus Biosciences Inc (CHRS)?
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter.
13G Filing: Partner Fund Management and Coherus Biosciences Inc. (CHRS)
You can access the original SEC filing by clicking here.
Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback
Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional...
Hedge Funds Are Betting On Coherus Biosciences Inc (CHRS)
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable...
AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS)
The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) has decided not to embark on the review of the 166 formulation patent of AbbVie Inc (NYSE:ABBV) ...
AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking
AbbVie Inc (NYSE:ABBV) and Coherus Biosciences Inc (NASDAQ:CHRS) were both off to a relatively normal start in the market today.
Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN)
Coherus Biosciences Inc (NASDAQ:CHRS) submitted a biologics licensing application (BLA) for its lead biosimilar development candidate earlier this month, and is drawing a lot ...
Yelp Inc (YELP) Swung To Surprising Profit; A Look at Four Other Earnings Reports
No major moves in the US stock market this Wednesday morning, as investors digest retail earnings reports and are keeping an eye on oil prices.
Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)’s Cancer Blockbuster
The biosimilar space is relatively young.
Why Coherus Biosciences, Hortonworks and 3 Other Stocks Are Posting Big Gains Today
The markets are off to a rocking start this week on the back of growing optimism after a strong jobs report on Friday, and waning uncertainty around the global economy after ...
13G Filing: Healthcare Royalty Partners III, L.p. and Coherus Biosciences, Inc. (CHRS)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent...
Venrock’s VHCP Management’s Top Picks For 2016
At Insider Monkey, we look at the weighted average returns of the long positions a fund indicates in its 13F filings, in companies with a market cap greater than $1 billion, ...
Why Are Investors Spooked About These 4 Stocks Today?
With many market participants on edge given the impending FOMC meeting next week and the plunging crude prices, shares of Kite Pharma Inc (NASDAQ:KITE), Qunar Cayman Islands Ltd...
Here Is What Hedge Funds Think Of Coherus Biosciences Inc (CHRS)
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government.
JUNO Therapeutics Inc (JUNO); Coherus Biosciences Inc (CHRS), Stemline Therapeutics Inc (STML): VCHP’s Bullish Sentiment Pays Off
Juno Therapeutics Inc (NASDAQ:JUNO) is up by 15% as of Thursday afternoon, following the release of its first-ever earnings report since its IPO.
